# Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

> **NCT06062498** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 174 (estimated)

## Conditions studied

- Estrogen-receptor-positive Breast Cancer
- HER2/Neu-Negative Breast Cancer
- Advanced Breast Cancerv
- Metastatic Breast Cancer

## Interventions

- **DRUG:** elacestrant, palbociclib, abemaciclib, ribociclib

## Key facts

- **NCT ID:** NCT06062498
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-29
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062498, "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06062498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*